Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
Status: Recruiting
Location: See all (72) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female (sex at birth).
• Age 18 years or above at the time of signing the informed consent.
Locations
United States
Alabama
Pinnacle Research Group LLC
RECRUITING
Anniston
California
Diablo Clinical Research, Inc.
RECRUITING
Walnut Creek
Florida
Florida Inst For Clin Res LLC
RECRUITING
Orlando
Illinois
Endeavor Health
NOT_YET_RECRUITING
Skokie
Indiana
Midwest Inst For Clin Res
RECRUITING
Indianapolis
North Carolina
Medication Mgmnt, LLC_Grnsboro
RECRUITING
Greensboro
PMG Research of Wilmington LLC
RECRUITING
Wilmington
Pennsylvania
UPA Ctr Weight and Eating Dis
RECRUITING
Philadelphia
Rhode Island
Clinical Res Collaborative
RECRUITING
Cumberland
Texas
North Texas Endocrine Center
NOT_YET_RECRUITING
Dallas
UT Southwestern Med Cntr
RECRUITING
Dallas
Virginia
Selma Medical Associates
RECRUITING
Winchester
Washington
Rainier Clin Res Ctr Inc
RECRUITING
Renton
Other Locations
Argentina
CIPREC Pueyrredon
RECRUITING
Buenos Aires
Conexa
RECRUITING
Ciudad Autonoma De Buenos Aires
CICEMO- Consultorio (Av Directorio)
RECRUITING
Ciudad Autónoma De Buenos Aires
Instituto de Investigaciones Clinicas Mar Del Plata
RECRUITING
Mar Del Plata
Australia
Nightingale Research
RECRUITING
Adelaide
Sydney Clinical Trials
RECRUITING
Campbelltown
Sydney Cardiometabolic Centre
RECRUITING
Liverpool
Hunter Diabetes Centre
RECRUITING
Merewether
Belgium
Anima Research Center
RECRUITING
Diepenbeek
AZ Groeninge - Kortrijk - Centrum Endo - Diabetologie
RECRUITING
Kortrijk
Centre hospitalier universitaire de Liège (CHU de Liège)
NOT_YET_RECRUITING
Liège
AZ OOSTENDE (Campus DAMIAAN)
NOT_YET_RECRUITING
Ostend
Bulgaria
DCC 1 - Lom EOOD
RECRUITING
Lom
AIPSOMCEMD ENDO MED CONSULT 2020 - Dr. Aleksander Botushanov EOOD
RECRUITING
Plovdiv
MHAT Med Line Clinic
RECRUITING
Plovdiv
UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
RECRUITING
Plovdiv
AIPSMC Dr. Traykovska EOOD
RECRUITING
Sofia
Medical Center Maraya Med EOOD
RECRUITING
Sofia
SGHAT Dr. Shterev EOOD
RECRUITING
Sofia
UMHAT Aleksandrovska EAD, Clinic of Endocrinology and Metabolic Diseases
RECRUITING
Sofia
Denmark
Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden
RECRUITING
Esbjerg
Sjællands Universitetshospital, Køge - Medicinsk Afdeling
RECRUITING
Køge
Sanos Clinic - Vejle
RECRUITING
Vejle
France
CHU DE CLERMONT-FERRAND-HOPITAL GABRIEL MONTPIED_Service de Nutrition
RECRUITING
Clermont-ferrand
CHU GRENOBLE ALPES-SITE NORD MICHALLON_Endocrinologie,diabétologie,maladies de la nutrition
RECRUITING
La Tronche
GROUPE SOS SANTE-HOPITAL LE CREUSOT-HOTEL DIEU_ Service de Diabétologie
RECRUITING
Le Creusot
CHU LILLE-HOPITAL CLAUDE HURIEZ_Service de Chirurgie Générale et Endocrinienne
RECRUITING
Lille
CHU DE POITIERS_Centre d'investigation Clinique
RECRUITING
Poitiers
Germany
Wendisch - Dahl Hamburg - DZHW
RECRUITING
Hamburg
Prof. Dr. Schiefke Ingolf, EUGASTRO GmbH
RECRUITING
Leipzig
Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
RECRUITING
Lingen
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
RECRUITING
Münster
RED-Institut für medizinische Forschung und Fortbildung GmbH
RECRUITING
Oldenburg In Holstein
Zentrum für klinische Studien Alexander Segner
RECRUITING
Saint Ingbert-oberwürzbach
Diabetologikum - Diabetologische Schwerpunktpraxis Dr. Thomas Segiet
RECRUITING
Speyer
Italy
A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura
RECRUITING
Bologna
Arcispedale Sant'Anna (Cona) - UO di Endocrinologia
NOT_YET_RECRUITING
Ferrara
IRCCS Ospedale Policlinico San Martino - Medicina Interna e Specialità Mediche
RECRUITING
Genoa
Azienda Ospedaliera di Padova - UOSD Chirurgia Bariatrica
NOT_YET_RECRUITING
Padova
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Presidio Villa Belmonte
RECRUITING
Palermo
Fondazione Salvatore Maugeri I.R.C.C.S. - Pavia - Dipartimento Medicina Interna e Generale
RECRUITING
Pavia
IRCCS Humanitas - U.O. Endocrinologia e Diabetologia
RECRUITING
Rozzano (mi)
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento - U.O. Geriatria
RECRUITING
Verona
Netherlands
Progress Clinical Research Den Bosch
RECRUITING
's-hertogenbosch
EB Flevo Research BV
RECRUITING
Almere Stad
Meander MC
NOT_YET_RECRUITING
Amersfoort
Rijnstate Ziekenhuis
RECRUITING
Arnhem
PreCare Trial & Recruitment
RECRUITING
Born
Spain
Centro Periferico De Especialidades Bola Azul
RECRUITING
Almería
Hospital Clinic i Provincial
RECRUITING
Barcelona
H. de León_Endocrinología
NOT_YET_RECRUITING
León
Hospital Clínico San Carlos
RECRUITING
Madrid
H. Clinico Univ. Virgen de la Victoria
RECRUITING
Málaga
H.U. Quirónsalud Madrid
RECRUITING
Pozuelo De Alarcón
Hospital Universitario Virgen del Rocío
RECRUITING
Seville
United Kingdom
EMS Healthcare
RECRUITING
Cheshire
Clifton Medical Centre
RECRUITING
Rotherham
Staploe Medical Centre
RECRUITING
Soham
Albany House Medical Centre
RECRUITING
Wellingborough
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2026-04-21
Estimated Completion Date: 2028-07-04
Participants
Target number of participants: 600
Treatments
Experimental: NNC0487-0111
Participants will receive subcutaneous injection of NNC0487-0111 once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Placebo_comparator: Placebo
Participants will receive subcutaneous injection of placebo matched to NNC0487-0111 once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S